Articles

BIO’s Greenwood: The Traditional Venture Capital Model is Broken

Expect to see more “co-opetition,” and increased government and private foundation in early stages, he said.
Post Date: 12/11/2012
Author: Agnes Shanley, Editor in Chief

Holiday Inspiration from Takeda's EVP, Tadataka Yamada

Become partners with emerging markets, in the broadest sense, he said, and always support, and embrace, revolutionary, rather than evolutionary change.
Post Date: 12/11/2012
Author: Agnes Shanley, Editor in Chief

Funny Pharm: You Write the Caption & Win: December 2012

"Funny Pharm," features drawings by award-winning cartoonist Jerry King. Submit your caption and win
Post Date: 12/05/2012
Author:

Digital Insights: Study Tracks Social Media

Academic study finds companies can use social media not only to collect consumer feedback, but also to alert FDA to drug problems and reactions.
Post Date: 11/29/2012
Author: Michele V. Wagner, Senior Digital Editor

BMS Wins Emerson’s Innovation Award for its Devens Facility

At the Emerson Global Users Exchange in Anaheim California last week, BMS was awarded the Innovation award for most innovative application of Emerson technologies at its new facility in Devens, Massachusetts, which received FDA approval for manufacturing earlier this year.
Post Date: 10/17/2012
Author: Agnes Shanley, Editor in Chief

Regulatory Harmonization Failures . . . and Prescriptions for Success

It’s time for Simultaneous Global Development (SGD), which requires addressing the lack of globally consistent, science- and risk-based regulatory requirements.
Post Date: 08/28/2012
Author: Regulatory Harmonization Institute

Are Single-Use Standards Stuck? And Is That a Bad Thing?

Efforts to enact meaningful standards for single-use bioprocessing technologies move at a snail's pace, with no clear path forward, experts say.
Post Date: 06/21/2012
Author: Paul Thomas, Senior Editor

Town Hall: FDA Braces for PDUFA V, Possible Loss of Biosimilars Authority

Janet Woodcock looks forward to having more cash and resources with new user fee legislation. Meanwhile, she raises concerns about the Agency’s authority over biosimilars should the Supreme Court strike down the Affordable Care Act.
Post Date: 06/20/2012
Author: Paul Thomas, Senior Editor

Regulation of Personalized Medicine: A Status Report

Expect evolution within the industry, as well as at FDA, as personalized medicine becomes the standard, rather than the exception, to biomedical innovation and product development.
Post Date: 06/12/2012
Author: Antoinette F. Konski, Partner, Foley and Lardner LLP

Digital Insights: Social Media Dislikes Pharma?

How do we measure the impact of social media? It’s a question being addressed by most drug companies, who have their own theories and formulas.
Post Date: 05/23/2012
Author: Michele V. Wagner, Senior Digital Editor

Today's Pharma: Big Challenges, Big Expectations

In an industry that faces great risk, change comes slowly—but it does come.
Post Date: 05/22/2012
Author: Nancy Berg, President, ISPE

Pfizer Newbridge Powers Up

Michael Donlon and Dermot Doran of Pfizer Newbridge discuss the challenges and success of the site’s YOU Have the Power project.
Post Date: 05/17/2012
Author: Paul Thomas, Senior Editor

Pharma Sustainability Is on a Roll

Drug industry environmental stewardship projects are becoming more sophisticated and challenging. Here are examples from AstraZeneca, Bayer, DSM, Pfizer, and EMD Millipore
Post Date: 05/16/2012
Author: Paul Thomas, Senior Editor

PharmaView: Carrots, Sticks, and CEOs

Salary does not dictate motivation and performance.
Post Date: 05/09/2012
Author: Paul Thomas, Senior Editor

With a Full Range of Products, EMD Millipore Turns Its Attention to Solutions

The company aims to leverage the expertise it has always had in-house, yet hadn’t fully capitalized on with the pharma industry, says VP Christophe Couturier.
Post Date: 05/02/2012
Author: Paul Thomas, Senior Editor

PharmaView: Who Will Be Pharma's Kane Waselenchuk?

As conventional ways of making drugs give way, we will seek out these people and value their brilliance.
Post Date: 04/23/2012
Author: Paul Thomas, Senior Editor

Pharma Jobs Are (Still) Going to Carolina

BioNetwork’s Doug Drabble says there are jobs throughout the state, though workers won't always relocate to take them.
Post Date: 04/17/2012
Author:

Digital Insights: Pinterest for Pharma?

Does Pharma have a place on Pinterest?
Post Date: 04/11/2012
Author: Michele V. Wagner, Senior Digital Editor

From the Editor: Pangloss or Popper: Has Drug Manufacturing Advanced in the Past Decade?

Can drug manufacturing reach its potential without standards, science and an admission that there’s a need for improvement?
Post Date: 04/11/2012
Author: Agnes Shanley, Editor in Chief

The Pulse of Pharmaceutical Manufacturing

The big picture has changed very little in ten years. While pointing out root causes, observers also see reasons for optimism.
Post Date: 04/04/2012
Author: Agnes Shanley, Editor in Chief